Holen Sie sich die Stockscreener-App
6.655
0.22%
-0.015
Handel nachbörslich:
6.70
0.045
+0.68%
Schlusskurs vom Vortag:
$6.67
Offen:
$6.605
24-Stunden-Volumen:
15,415
Relative Volume:
0.76
Marktkapitalisierung:
$30.30M
Einnahmen:
$85.53M
Nettoeinkommen (Verlust:
$-9.78M
KGV:
-3.0316
EPS:
-2.1952
Netto-Cashflow:
$1.28M
1W Leistung:
+2.86%
1M Leistung:
+12.23%
6M Leistung:
+20.00%
1J Leistung:
+35.98%
1-Tages-Spanne:
$6.51
$6.70
1-Wochen-Bereich:
$6.05
$6.70
52-Wochen-Spanne:
$3.755
$9.40
Harvard Bioscience Inc Stock (HBIO) Company Profile
Firmenname
Harvard Bioscience Inc
Sektor
Telefon
(508) 893-8999
Adresse
84 OCTOBER HILL RD, HOLLISTON, MA
Compare HBIO vs ISRG, BDX, ALC, RMD, MDLN
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HBIO
Harvard Bioscience Inc
|
6.655 | 28.09M | 85.53M | -9.78M | 1.28M | -2.1952 |
ISRG
Intuitive Surgical Inc
|
394.51 | 141.76B | 11.03B | 3.16B | 3.22B | 8.7251 |
BDX
Becton Dickinson Co
|
183.40 | 50.00B | 21.37B | 1.41B | 3.07B | 3.9437 |
ALC
Alcon Inc
|
74.25 | 35.57B | 10.63B | 819.00M | 1.59B | 1.6577 |
RMD
Resmed Inc
|
224.46 | 32.78B | 5.54B | 1.52B | 1.74B | 10.37 |
MDLN
Medline Inc
|
35.74 | 31.15B | 29.14B | 1.07B | 1.05B | 1.1956 |
Harvard Bioscience Inc Stock (HBIO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-09 | Herabstufung | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2023-03-10 | Hochstufung | The Benchmark Company | Speculative Buy → Buy |
| 2021-01-07 | Hochstufung | The Benchmark Company | Speculative Buy → Buy |
| 2020-12-09 | Eingeleitet | Northland Capital | Outperform |
| 2020-11-10 | Eingeleitet | KeyBanc Capital Markets | Overweight |
| 2019-07-08 | Herabstufung | Janney | Buy → Neutral |
| 2018-01-24 | Bestätigt | Janney | Buy |
| 2018-01-23 | Bestätigt | The Benchmark Company | Buy |
| 2016-11-17 | Eingeleitet | Singular Research | Buy |
| 2015-07-28 | Eingeleitet | The Benchmark Company | Buy |
Alle ansehen
Harvard Bioscience Inc Aktie (HBIO) Neueste Nachrichten
Benchmark raises Harvard Bioscience stock price target on revenue beat By Investing.com - Investing.com South Africa
HBIO Maintained by Benchmark -- Price Target Raised to $7.50 - GuruFocus
Benchmark raises Harvard Bioscience stock price target on revenue beat - Investing.com
Harvard Bioscience, Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:HBIO) 2026-08-12 - Seeking Alpha
Harvard Bioscience, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
HARVARD BIOSCIENCE INC 2026: Revenue $22.73M, EPS ($0.64) — 10-Q Summary - TradingView
Harvard Bioscience (NASDAQ: HBIO) grows Q2 sales but faces higher debt costs - Stock Titan
Harvard Bioscience Inc (HBIO) (Q2 2026) Earnings Call Highlights - GuruFocus
HBIO Looks 66.8% Undervalued on GF Value™ Despite Profitability Challenges - GuruFocus
Harvard Bioscience Inc (HBIO) (Q2 2026) Earnings Call Highlights: Revenue Surges 11% and ... - Yahoo Finance
Harvard Bioscience Releases Q2 2026 Financial Results - AlphaStreet
Earnings call transcript: Harvard Bioscience tops Q2 2026 forecasts, raises outlook - Investing.com Nigeria
HBio Q2 2026 slides: revenue up 11%, China growth drives guidance raise - Investing.com Nigeria
Harvard Bioscience beats Q2 estimates and raises 2026 revenue guidance - Yahoo Finance
Harvard Bioscience beats estimates, raises 2026 guidance - Investing.com
Harvard Bioscience Raises Full-Year 2026 Revenue Guidance After Strong Second-Quarter Growth - Minichart
Why is Harvard Bioscience stock gaining today? By Investing.com - Investing.com Canada
Is Harvard Bioscience Inc (HBIO) Undervalued After Q2 Earnings B - GuruFocus
Harvard Bioscience beats estimates, raises 2026 guidance By Investing.com - Investing.com South Africa
Harvard Bioscience Announces Second Quarter 2026 Financial Results - The Manila Times
Harvard Bioscience: Q2 Earnings Snapshot - marketscreener.com
Harvard Bioscience Q2 revenue rises on telemetry demand, lifts 2026 outlook - TradingView
Harvard Bioscience Q2 Revenue Rises 11 Percent to $22.7 Million - Quiver Quantitative
Harvard Bioscience (HBIO) grows Q2 2026 sales but stays in loss - Stock Titan
BRIEF-Harvard Bioscience Q2 Net Income USD -2.91 Million - TradingView
Harvard Bioscience, Inc. Provides Earnings Guidance for the Third Quarter of 2026 - marketscreener.com
Harvard Bioscience Inc (HBIO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Harvard Bioscience Inc expected to post a loss of 21 cents a shareEarnings Preview - TradingView
Harvard Bioscience Q2 Results: Earnings Call Set for August 11 - scanx.trade
Harvard Bioscience Schedules Second Quarter 2026 Earnings Conference Call for August 11, 2026 at 8:00 AM ET - The Manila Times
Harvard Bioscience Schedules Second Quarter 2026 Earnings Conference Call for August 11, 2026 ... - Caledonian Record
Harvard Bioscience Inc (HBIO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Harvard Bioscience Inc (HBIO) Cash Flow - TradingKey
Harvard Bioscience Inc (HBIO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Harvard Bioscience Inc (HBIO) Valuation: PE, PB & Fair Value Analysis - TradingKey
Harvard Bioscience Inc (HBIO) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Harvard Bioscience Inc (HBIO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
HBIO|Harvard Bioscience Inc|Price:6.000|Chg%:-0.190 - TradingKey
Harvard Bioscience, Inc. Revenue Breakdown – MUN:HBI0 - TradingView
Harvard Bioscience, Inc. Revenue Breakdown – LS:A423J5 - TradingView
Harvard Bioscience, Inc. Revenue Breakdown – NASDAQ:HBIO - TradingView
Harvard Bioscience, Inc. Revenue Breakdown – LSX:A423J5 - TradingView
HBIO Stock Price, Quote & Chart - ChartMill
Harvard Bioscience Inc (HBIO) Institutional Confidence - TradingKey
HBIO Q2'26 Earnings: revenue estimate is 21.45M USD - TradingView
Harvard Bioscience focuses on life science instruments as investors weigh long-term demand - ad-hoc-news.de
Harvard Bioscience (HBIO) Slips 4.5% as Selling Pressure Tests Key SupportETF Inflow Streak - po-news-eg.net
Harvard Bioscience focuses on lab equipment growth - Ad-hoc-news.de
Harvard Bioscience (HBIO) Hovers Near Support Amid Low-Volume TradingBollinger Walk - dars.gov.et
Harvard Bioscience | SD: Specialized disclosure report - Moomoo
Harvard Bioscience, Inc. Actuals & Estimates (NASDAQ:HBIO) - TradingView
Finanzdaten der Harvard Bioscience Inc-Aktie (HBIO)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.90%
1.18%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):